AA
NGM

ALPS Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

ALPS Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-54,054
Closed -$221K – 1040
2023
Q1 		$221K Sell
54,054
-1,466
-3% -$6.78K ﹤0.01% 975
2022
Q4 		$279K Buy
+55,520
New +$348K ﹤0.01% 926

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ALPS Advisors's NGM Position: Q2 2023 in Review

ALPS Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 54,054 shares — an estimated $221K sold.

ALPS Advisors first reported a position in NGM in Q4 2022 and held it in 2 quarters. The position peaked at $279K in Q4 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

  • ALPS Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 54,054 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $221K.
  • ALPS Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • ALPS Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $279K in Q4 2022.
  • 106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.